insights_auto
Why is DRUG up 4.87%?
Dive Deeperchevron_right
DRUG:CNSX
Bright Minds Biosciences Inc
CA$77.10
arrow_upward
+4.87%(+3.58) 1D
Oct 9, 4:00:00 PM GMT-4 · CAD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DRUG...
Open
CA$76.13
High
CA$77.76
Low
CA$76.13
Mkt. cap
760.52M
Avg. vol.
865.00
Volume
0.00
52-wk high
CA$170.00
52-wk low
CA$68.02
EPS
-CA$2.90
No. of employees
26
Open
CA$76.13
High
CA$77.76
Low
CA$76.13
Mkt. cap
760.52M
Avg. vol.
865.00
Volume
0.00
52-wk high
CA$170.00
52-wk low
CA$68.02
EPS
-CA$2.90
No. of employees
26
News stories
From web sources and news partners
StreetInsider
·
19 minutes ago
Global S&P Futures mixed in premarket
The Motley Fool
·
39 minutes ago
Prediction: A Stock Market Crash Is Coming. Here's What Investors Should Do Based on Almost 7 Decades' Worth of History.
JournalArta
·
24 minutes ago
Buffett’s 90% S&P 500 Plan: What to Know
BeInCrypto
·
6 hours ago
Citi Says S&P 500 Needs AI and Non-AI Stocks to Reach 8,100
Profile
Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use.
It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens.
The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York. Wikipedia
About Bright Minds Biosciences Inc